Introduction: Heart failure (HF) is a major public health issue associated with significantly
increased risk of stroke. It remains uncertain whether oral anticoagulation (OAC) in patients …

Background: The medical management of left ventricular thrombus (LVT) is very challenging
due to the risk of embolic events. The current body of evidence supports the use of DOACs …

Background. This meta‐analysis was performed to compare the efficacy and safety of direct
oral anticoagulants (DOACs) with vitamin K antagonists (VKAs) for stroke prevention in real …

Atrial fibrillation (AF) is the most common cardiac arrhythmia. It was estimated to affect up to
6.1 million Americans in 2010, and since AF is more common with increasing age, it is …

Background Patients with atrial fibrillation (AF) and bioprosthetic valves (BPV) require long-
term anticoagulation and current recommendations support the use of vitamin K antagonists …

Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral
anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Left ventricular thrombus (LVT), one of the most feared and common complications of acute
myocardial infarction (AMI), still causes morbidity and mortality in a proportion of patients …

We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC)
treatment. A search of the medical literature was performed from inception until May 31 …